Policy & Regulation
Symvivo Receives Funding for COVID-19 Vaccine Program
21 October 2020 - - Canada-based biotechnology company Symvivo Corp. is receiving advisory services and funding of up to USD 2.8m from the National Research Council Industrial Research Assistance Program (NRC IRAP) to support the clinical advancement of bacTRL-Spike, the company's oral, room temperature-stable DNA vaccine candidate for the prevention of COVID-19, the company said.

The funding follows a notification Symvivo received from the government of Canada indicating it had reviewed Symvivo's proposal and its bacTRL-Spike vaccine candidate had met the required scientific and technical thresholds for funding.

Unlike traditional vaccines, bacTRL-Spike is a capsule that can be taken orally, allowing individuals to self-administer the vaccine rather than requiring a trained medical professional to deliver it with an injection. In addition, the capsules can also be stored at room temperature.

Symvivo is a clinical-stage biotechnology company advancing a proprietary platform for the site specific delivery of genes for the treatment and prevention of disease.

Symvivo's bacTRL platform technology delivers plasmid DNA, both orally and through IV application, that enables a patient's own cells to produce therapeutic proteins. Symvivo is advancing therapeutics in the area of oral DNA vaccines, oncology, immunology and gene replacement. Symvivo is headquartered in Burnaby BC.


Related Headlines